METTL16 and pancreatic adenocarcinoma: Mechanistically, METTL16 inhibits DVL2 translation via m6A modification, thereby regulating the Wnt/β-catenin signaling pathway; METTL16 downregulation leads to elevated DVL2 levels, promoting PAAD progression (39).